ART 5
Alternative Names: ART-5Latest Information Update: 28 Nov 2025
At a glance
- Originator Arnatar Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action Gene silencing; PKD1 protein expression stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autosomal dominant polycystic kidney disease
Most Recent Events
- 20 Oct 2025 Pharmacodynamics data from preclinical studies in Autosomal dominant polycystic kidney disease released by Arnatar Therapeutics
- 17 Sep 2025 Preclinical trials in Autosomal dominant polycystic kidney disease in USA (SC), prior to September 2025 (Arnatar Therapeutics pipeline, September 2025)
- 17 Sep 2025 Adverse events and pharmacodynamics data from preclinical trials in Autosomal dominant polycystic kidney disease released by Arnatar Therapeutics (Arnatar Therapeutics pipeline, September 2025)